Clinical Trials

Formal Study Name

Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy

Histology

Acute Myeloid Leukemia

Trial Phase

2

Trial Type

Interventional

Principal Investigator

Salil Goorha, MD

Locations Where Open

• Baptist Cancer Center-Humphreys
• Baptist Cancer Center-Walnut Grove
• Baptist Cancer Center-Bartlett
• Baptist Cancer Center-Collierville
• Baptist Cancer Center - DeSoto
• Baptist Cancer Center-Grenada
• Baptist Cancer Center- Golden Triangle Columbus
• Baptist Cancer Center- Golden Triangle Starkville
• Baptist Cancer Center-New Albany
• Baptist Cancer Center-Oxford

Formal Study Name

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Histology

Small Cell Carcinoma

Treatment Phase

Locally Advanced or Metastic

Trial Phase

1

Trial Type

Interventional

Principal Investigator

Philip Lammers, MD

Locations Where Open

• Baptist Cancer Center-Humphreys

Formal Study Name

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

Histology

ER Positive, HER2 Negative

Treatment Phase

Adjuvant

Trial Phase

3

Trial Type

Interventional

Principal Investigator

Philip Lammers, MD

Locations Where Open

• Baptist Cancer Center-Humphreys
• Baptist Cancer Center-Memphis 6029 Walnut Grove
• Baptist Cancer Center-Bartlett
• Baptist Cancer Center-Collierville
• Baptist Cancer Center - DeSoto

Formal Study Name

Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

Histology

Clear Cell Renal Cell Carcinoma

Stage

2 to 3

Treatment Phase

Adjuvant

Trial Phase

3

Trial Type

Interventional

Principal Investigator

Osa Ogbeide, MD

Locations Where Open

• Baptist Cancer Center-Humphreys
• Baptist Cancer Center-Memphis 6029 Walnut Grove
• Baptist Cancer Center-Bartlett
• Baptist Cancer Center-Collierville
• Baptist Cancer Center - DeSoto
• Baptist Cancer Center-Grenada
• Baptist Cancer Center- Golden Triangle Columbus
• Baptist Cancer Center- Golden Triangle Starkville
• NEA Baptist Fowler Family Center for Cancer Care
• Baptist Cancer Center-New Albany
• Baptist Cancer Center-Oxford

Formal Study Name

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Histology

Non-squamous

Stage

4 and limited 1 - 3

Treatment Phase

Metastatic

Trial Phase

3

Trial Type

Interventional

Principal Investigator

Philip Lammers, MD

Locations Where Open

• Baptist Cancer Center-Humphreys
• Baptist Cancer Center-Walnut Grove
• Baptist Cancer Center-Bartlett
• Baptist Cancer Center-Collierville
• Baptist Cancer Center - DeSoto
• Baptist Cancer Center-Oxford
• Baptist Cancer Center-New Albany
• Baptist Cancer Center-Grenada
• Baptist Cancer Center- Golden Triangle Columbus
• Baptist Cancer Center- Golden Triangle Starkville
• NEA Baptist Fowler Family Center for Cancer Care

Formal Study Name

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

Treatment Phase

Refractory

Trial Phase

2

Trial Type

Interventional

Principal Investigator

Sharon Dowell, MD

Locations Where Open

• Baptist Cancer Center-Walnut Grove
• NEA Baptist Fowler Family Center for Cancer Care

Formal Study Name

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Trial Type

Interventional

Principal Investigator

Abdullah Al-Rashdan, MD

Locations Where Open

• Baptist Cancer Center-Humphreys

Formal Study Name

Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma

Treatment Phase

Recurrent

Trial Phase

2

Trial Type

Interventional

Principal Investigator

Drew Dill, MD

Locations Where Open

• Baptist Cancer Center-Humphreys
• Baptist Cancer Center-Walnut Grove
• Baptist Cancer Center-Bartlett
• Baptist Cancer Center-Collierville
• Baptist Cancer Center - DeSoto
• Baptist Cancer Center-Grenada
• NEA Baptist Fowler Family Center for Cancer Care
• Baptist Cancer Center-New Albany
• Baptist Cancer Center-Oxford

Formal Study Name

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)

Stage

4

Treatment Phase

1B

Trial Phase

1/2

Trial Type

Interventional

Principal Investigator

Philip Lammers, MD

Locations Where Open

• Baptist Cancer Center-Humphreys
• Baptist Cancer Center-Walnut Grove
• Baptist Cancer Center-Bartlett
• Baptist Cancer Center-Collierville
• Baptist Cancer Center - DeSoto

Formal Study Name

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)

Trial Phase

3

Trial Type

Interventional

Principal Investigator

Brion Randolph, MD

Locations Where Open

• Baptist Cancer Center-Memphis Malignant Hematology & Stem Cell Clinic